---
layout: default
title: Cladribine
description: "Cladribine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 7 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 48
evidence_level: L5
indication_count: 7
---

# Cladribine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>7</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Cladribine è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Cladribine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Cladribine æ˜¯ä¸€ç¨®æ ¸è‹·é¡ä¼¼ç‰©æŠ—è…«ç˜¤è—¥ï¼Œç›®å‰æ ¸å‡†ç”¨æ–¼å¤šç™¼æ€§ç¡¬åŒ–ç—‡åŠæ¯›é«®ç‹€ç´°èƒç™½è¡€ç—…ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°æ©«ç´‹è‚Œè‚‰ç˜¤åŠè‚è‡Ÿè‚‰ç˜¤ç­‰ç½•è¦‹è…«ç˜¤æœ‰ç™‚æ•ˆï¼Œä½†ç›®å‰ç¼ºä¹è‡¨åºŠè­‰æ“šæ”¯æŒã€‚
</p>


---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Cladribine (å…‹æ‹‰å±ˆæ¿±) |
| DrugBank ID | DB00242 |
| å°ç£å•†å“å | ç‘ªå¨å…‹éŒ  10 æ¯«å…‹ (Mavenclad)ã€ç¥¿æ–¯å¾—åœæ³¨å°„åŠ‘ (Leustatin) |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | å¾©ç™¼å‹å¤šç™¼æ€§ç¡¬åŒ–ç—‡ã€æ¯›é«®ç‹€ç´°èƒç™½è¡€ç—… |
| é æ¸¬æ–°é©æ‡‰ç—‡ | parameningeal embryonal rhabdomyosarcomaã€botryoid-type embryonal rhabdomyosarcoma of the vaginaã€embryonal extrahepatic bile duct rhabdomyosarcomaã€prostate embryonal rhabdomyosarcomaã€extrahepatic bile duct rhabdomyosarcomaã€rhabdomyosarcoma (disease)ã€liver sarcoma |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.998 (parameningeal embryonal rhabdomyosarcoma) |
| è­‰æ“šç­‰ç´š | L5 (åƒ…é æ¸¬) |

---

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

Cladribine æ˜¯ä¸€ç¨®å˜Œå‘¤æ ¸è‹·é¡ä¼¼ç‰©ï¼Œå…·æœ‰å¼·æ•ˆçš„æŠ—å¢æ®–åŠå…ç–«èª¿ç¯€ä½œç”¨ã€‚å…¶ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š

1. **DNA åˆæˆæŠ‘åˆ¶**ï¼šCladribine é€²å…¥ç´°èƒå¾Œè¢«ç£·é…¸åŒ–ç‚ºæ´»æ€§ä»£è¬ç‰©ï¼Œå¹²æ“¾ DNA åˆæˆèˆ‡ä¿®å¾©
2. **æ·‹å·´ç´°èƒæ¯’æ€§**ï¼šé¸æ“‡æ€§åœ°å°æ·‹å·´ç´°èƒç”¢ç”Ÿç´°èƒæ¯’æ€§ï¼Œé€™ä¹Ÿæ˜¯å…¶ç”¨æ–¼æ²»ç™‚æ¯›é«®ç‹€ç´°èƒç™½è¡€ç—…çš„åŸºç¤
3. **å»£è­œæŠ—è…«ç˜¤æ´»æ€§**ï¼šä½œç‚ºæ ¸è‹·é¡ä¼¼ç‰©ï¼Œç†è«–ä¸Šå°å¿«é€Ÿåˆ†è£‚çš„è…«ç˜¤ç´°èƒæœ‰æŠ‘åˆ¶ä½œç”¨

æ©«ç´‹è‚Œè‚‰ç˜¤å±¬æ–¼è»Ÿçµ„ç¹”è‚‰ç˜¤ï¼Œå‚³çµ±ä¸Šä½¿ç”¨ VAC (vincristine, actinomycin D, cyclophosphamide) æ–¹æ¡ˆæ²»ç™‚ã€‚çŸ¥è­˜åœ–è­œé æ¸¬ cladribine å¯èƒ½å°æ­¤é¡è…«ç˜¤æœ‰æ•ˆï¼Œå¯èƒ½åŸºæ–¼å…¶èˆ‡å…¶ä»–æ ¸è‹·é¡æŠ—è…«ç˜¤è—¥ç‰©çš„çµæ§‹ç›¸ä¼¼æ€§ã€‚

---

## è‡¨åºŠè©¦é©—è­‰æ“š

ç›®å‰ **ç„¡** é‡å° cladribine ç”¨æ–¼æ©«ç´‹è‚Œè‚‰ç˜¤æˆ–è‚è‡Ÿè‚‰ç˜¤çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

---

## æ–‡ç»è­‰æ“š

| PMID | æ¨™é¡Œ | ç›¸é—œæ€§ |
|------|------|--------|
| 15241520 | Smoldering systemic mastocytosis - Successful therapy with cladribine | é–“æ¥è­‰æ“šï¼šCladribine å°è‚¥å¤§ç´°èƒå¢ç”Ÿç—‡æœ‰æ•ˆï¼Œé¡¯ç¤ºå…¶å°æŸäº›é€ è¡€ç³»çµ±è…«ç˜¤çš„æ´»æ€§ |

æ–‡ç»ä¸­é—œæ–¼ cladribine ç”¨æ–¼è‚è‡Ÿè‚‰ç˜¤çš„å ±å‘Šå¯¦éš›ä¸Šæ˜¯é—œæ–¼å…¨èº«æ€§è‚¥å¤§ç´°èƒå¢ç”Ÿç—‡çš„å€‹æ¡ˆï¼Œèˆ‡é æ¸¬é©æ‡‰ç—‡çš„ç›´æ¥ç›¸é—œæ€§æœ‰é™ã€‚

---

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | é©æ‡‰ç—‡ | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | ç‹€æ…‹ |
|------------|--------|--------|------|--------------|------|
| è¡›éƒ¨ç½•è—¥è¼¸å­—ç¬¬000058è™Ÿ | ç‘ªå¨å…‹éŒ  10 æ¯«å…‹ | å¾©ç™¼å‹å¤šç™¼æ€§ç¡¬åŒ–ç—‡ | éŒ åŠ‘ | å°ç£é»˜å…‹è‚¡ä»½æœ‰é™å…¬å¸ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬021992è™Ÿ | ç¥¿æ–¯å¾—åœæ³¨å°„åŠ‘ | æ¯›é«®ç‹€ç´°èƒç™½è¡€ç—… | æ³¨å°„åŠ‘ | è£•åˆ©è‚¡ä»½æœ‰é™å…¬å¸ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è£½å­—ç¬¬061006è™Ÿ | å°ç£ç¥éš†å…‹æ‹‰å±ˆæ¿± | å¾©ç™¼å‹å¤šç™¼æ€§ç¡¬åŒ–ç—‡ | åŸæ–™è—¥ | å°ç£ç¥éš†è‚¡ä»½æœ‰é™å…¬å¸ | æœ‰æ•ˆ |

---

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è—¥ç‰©äº¤äº’ä½œç”¨ (Major)

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | è‡¨åºŠæ„ç¾© |
|--------------|----------|----------|
| çš®è³ªé¡å›ºé†‡ (Hydrocortisone, Prednisolone, Dexamethasone ç­‰) | Major | å¢åŠ å…ç–«æŠ‘åˆ¶é¢¨éšª |
| å…ç–«æŠ‘åˆ¶åŠ‘ (Tacrolimus, Azathioprine) | Major | åŠ é‡éª¨é«“æŠ‘åˆ¶ |
| æŠ—ç—…æ¯’è—¥ (Zidovudine, Ganciclovir) | Major | éª¨é«“æ¯’æ€§ç–ŠåŠ  |
| å…¶ä»–åŒ–ç™‚è—¥ç‰© (Gemcitabine, Mercaptopurine) | Major | å¢åŠ è¡€æ¶²å­¸æ¯’æ€§ |
| æ”¾å°„æ€§è—¥ç‰© | Major | åŠ é‡éª¨é«“æŠ‘åˆ¶ |

### ä¸»è¦è­¦èª

- åš´é‡éª¨é«“æŠ‘åˆ¶ï¼šå¯èƒ½å°è‡´æ„ŸæŸ“ã€å‡ºè¡€é¢¨éšªå¢åŠ 
- å…ç–«æŠ‘åˆ¶ï¼šé•·æœŸæ·‹å·´ç´°èƒæ¸›å°‘ï¼Œå¢åŠ æ©Ÿæœƒæ€§æ„ŸæŸ“é¢¨éšª
- è‡´ç•¸æ€§ï¼šå­•å©¦ç¦ç”¨ï¼Œè‚²é½¡å©¦å¥³éœ€æœ‰æ•ˆé¿å­•

---


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- The pharmacokinetic disposition of cladribine has not be fully assessed. The effect of hepatic impairment on the elimination of cladribine is not known.  Therapy with cladribine should be administered cautiously in patient with existing or predisposi...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- The effect of renal impairment on the elimination of cladribine has not been assessed in humans.  Renal toxicity such as acidosis, anuria, elevated serum creatinine has been reported with doses four to nine times the recommended dosage of cladribine ...

**Infections** ğŸŸ¢ Minor
- Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All pat...

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- Cladribine induces myelosuppression, primarily affecting lymphocytes and monocytes, however, neutropenia, anemia, and thrombocytopenia have been reported during cladribine therapy.  Myelosuppressive effects are most notable the first month following ...

**Nervous System Diseases** ğŸŸ¢ Minor
- Severe unspecified neurological toxicity has been reported rarely during cladribine therapy administered at therapeutic doses.  Serious neurological toxicity such as irreversible paraparesis and quadriparesis has been reported in patients receiving f...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬è©•ä¼°

| è©•ä¼°é …ç›® | çµæœ |
|----------|------|
| æ©Ÿè½‰åˆç†æ€§ | ä¸­ç­‰ - æ ¸è‹·é¡ä¼¼ç‰©å°å¿«é€Ÿåˆ†è£‚ç´°èƒæœ‰å»£è­œæ´»æ€§ |
| è‡¨åºŠè­‰æ“š | ç„¡ |
| æ–‡ç»æ”¯æŒ | æ¥µå¼± |
| æ•´é«”è­‰æ“šç­‰ç´š | **L5 (åƒ…é æ¸¬)** |

### å»ºè­°

1. **ä¸å»ºè­°è‡¨åºŠä½¿ç”¨**ï¼šç›®å‰ç„¡è¶³å¤ è­‰æ“šæ”¯æŒ cladribine ç”¨æ–¼æ©«ç´‹è‚Œè‚‰ç˜¤æˆ–è‚è‡Ÿè‚‰ç˜¤
2. **å‰è‡¨åºŠç ”ç©¶éœ€æ±‚**ï¼šè‹¥æœ‰èˆˆè¶£æ¢ç´¢æ­¤é æ¸¬ï¼Œå»ºè­°å…ˆé€²è¡Œé«”å¤–ç´°èƒæ ªåŠå‹•ç‰©æ¨¡å‹ç ”ç©¶
3. **æŒçºŒç›£æ¸¬æ–‡ç»**ï¼šé—œæ³¨æ˜¯å¦æœ‰æ–°çš„è‡¨åºŠæˆ–åŸºç¤ç ”ç©¶ç™¼è¡¨

---

*æœ¬ç­†è¨˜åƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚ä»»ä½•ç”¨è—¥æ±ºç­–æ‡‰è«®è©¢å°ˆæ¥­é†«ç™‚äººå“¡ã€‚*

*æœ€å¾Œæ›´æ–°ï¼š2026-02-11*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Tenofovir Alafenamide]({{ "/drugs/tenofovir_alafenamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Felodipine]({{ "/drugs/felodipine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Lidocaine]({{ "/drugs/lidocaine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Iodixanol]({{ "/drugs/iodixanol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Potassium Iodide]({{ "/drugs/potassium_iodide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Cladribineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/cladribine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_cladribine,
  title = {Cladribineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/cladribine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
